What is it?
What it is
3Cerebrolysin contains peptides and amino acids derived from pig-brain proteins. This page concerns the injectable mixture, not an oral peptide supplement. Porcine means pig-derived.
Injection routes
9Intravenous (IV) administration enters a vein; intramuscular (IM) administration enters muscle. Cerebrolysin is supplied as a solution for injection, with route-specific clinical handling requirements.
Names, aliases and forms
Mechanisms of action
Porcine peptide mixture
7An analysis of one internet-obtained sample identified 638 peptides, mainly from structural pig-brain proteins. It did not identify fragments of the named nerve-growth factors BDNF or NGF. This does not prove that all internet products have the same composition.
Clinical research is population-specific
5Traumatic-brain-injury trials study recovery of function after injury. Those patient endpoints cannot establish a general brain-optimization effect.
Potential effects and evidence map
Evidence is mostly from clinical injection studies. Vascular-dementia findings are very uncertain; stroke reviews differ by outcome and study selection; traumatic-brain-injury trials report condition-specific signals. A small healthy-male infusion trial is insufficient to establish routine nootropic benefits.
Small cognition signals in vascular dementia trials have very low certainty and do not establish healthy-adult memory enhancement.
Clinical neurorecovery research does not establish general long-term brain protection in healthy adults.
Typical dosages and timing
CAPTAIN II used 50 mL/day for 10 days, followed by two 10-day cycles at 10 mL/day, alongside standard care after moderate-severe brain injury. These are study exposures, not a healthy-user dose or recommended cycle.
Timing & effect horizon
The healthy-volunteer study lasted 10 days. Its EEG observations and exploratory recall results do not establish a reliable onset, effect duration or cycle for everyday use. A single The time for blood levels to fall by half during the final elimination phase.Source for this peptide mixture was not established in the sources reviewed.
Safety, side effects and risk profile
As of 18 October 2026, the manufacturer states Cerebrolysin is not FDA-approved for sale or distribution in the United States.
Severe renal impairment is a contraindication in the Austrian prescribing-information summary.
The handbook warns of additive effects with antidepressants or MAO inhibitors, including reported blood-pressure increases with high-dose combinations.
Manufacturer guidance links administration speed with heart-rate, blood-pressure or rhythm effects; frequency in healthy users is not quantified.
The cited clinical evidence does not establish safety in pregnancy or lactation.
Stroke safety findings are population-specific; the Cochrane review identified a nonfatal serious-adverse-event signal.
The manufacturer handbook links administration speed with possible heart-rate, blood-pressure or rhythm effects. It does not provide an incidence estimate for healthy users.
Opened ampoules can become contaminated. The handbook specifies immediate use and sterile clinical handling; a seller description cannot verify sterility.
The 2023 Cochrane stroke review found little or no difference in total serious adverse events, but a possible increase in nonfatal serious events. These findings concern stroke patients receiving injections, not an oral supplement population.
In the small infusion trial, the highest dose produced mild events and a small blood-pressure decrease. The short observation period and male-only sample cannot establish long-term safety or safety of self-administration.
A 2025 meta-analysis found no significant difference in total serious adverse events or mortality. Its population and endpoint differ from the healthy-use question; a null total-event result does not remove the earlier nonfatal-event concern.
Interactions and cautions
The handbook warns of additive effects with antidepressants and MAO inhibitors, including blood-pressure increases in high-dose combinations. It does not establish a safe consumer stack.
The handbook distinguishes use alongside other medicines from mixing drugs together in an infusion. Compatibility is a clinical administration issue.
Legal and regulatory status
As of 18 October 2026, the manufacturer notice states that Cerebrolysin is not registered with the FDA and is not approved for sale or distribution in the United States. A storefront listing does not establish U.S. approval.
As of 18 October 2026, the manufacturer summary based on Austria's SmPC describes prescription-only pharmacy supply in Austria, an EU member state. This is country-specific product information, not a statement of EU-wide authorization; supply rules differ elsewhere.
Practical buying and quality notes
- An international offer is not proof of authorization in the destination country. U.S. status is described above; local access rules and clinical suitability are separate from price.1
- Compare total pack volume: ampoule volume multiplied by ampoule count. Five 5 mL ampoules contain 25 mL; five 10 mL ampoules contain 50 mL. Divide pack price by total mL only for the same formulation and currency. A milligram figure for concentrate is not a peptide potency measurement.9
- The analysis of one internet sample describes composition, not a sterility certificate or verification of current sellers. Lot, expiry and packaging information answer different questions from a chemical assay.7
FAQ
Is Cerebrolysin FDA-approved in the United States?
1No. As of 18 October 2026, the manufacturer U.S. notice states it is not FDA-approved for sale or distribution in the United States.
What Cerebrolysin dose has been studied?
6Published injection protocols differ by patient population. The clinical example above is not an oral dose, a self-injection protocol or evidence for a consumer cycle.
Is Cerebrolysin a nootropic for healthy people?
8A 1998 randomized study enrolled 48 healthy men receiving infusions. It examined EEG and short-term recall, including an experimental hyperventilation condition. Its small size and exploratory endpoints do not establish everyday nootropic benefit.
Why are Cerebrolysin listings hard to compare?
9Ampoule size and pack count change total volume; currencies and shipping change final cost. Compare like-for-like packs. A zero quantity or per-gram listing value is not a verified dose or reliable basis for a potency comparison.
References
- EVER Neuro Pharma. Cerebrolysin FAQs and notice to U.S. visitors.
- EVER Neuro Pharma. Cerebrolysin Treatment Handbook. 2023.
- Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023;10(10):CD007026.
- Cui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019;2019(11):CD008900.
- Vester JC, Buzoianu AD, Florian SI, et al. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021.
- Muresanu DF, Florian S, Homberg V, et al. Efficacy and safety of Cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial. Neurol Sci. 2020;41:1171-1181.
- Gevaert B, et al. Peptide profiling of Internet-obtained Cerebrolysin. Drug Test Anal. 2015;7(9):835-842.
- Funke M, et al. Dose-dependent effects of Cerebrolysin on EEG and short-term memory of healthy volunteers during control and hyperventilation induced cerebral ischemia. J Neural Transm Suppl. 1998;53:385-398.
- EVER Neuro Pharma. About Cerebrolysin: abbreviated prescribing information based on Austrian SmPC. Accessed 18 October 2026.
- Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials. 2025.